Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with type 2 diabetes

Trial Profile

Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with type 2 diabetes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Luseogliflozin (Primary) ; Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Apr 2017 Planned no of patients changed from 85 to 150.
    • 05 Apr 2017 Status changed from completed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top